Senestech, INC 8-K filings

SenesTech announced record Q2 2026 revenue of $770,000, a 56% sequential increase, alongside a company-record 73.6% gross margin, fueled by accelerated e-commerce growth.

SenesTech, Inc. announced its active online subscriber base more than doubled in Q2 2026, driven by a 186% growth in its e-commerce business.

SenesTech, Inc. held its 2026 annual meeting of stockholders, where directors were elected, executive compensation was approved advisory, and an amendment to the equity incentive plan was ratified.

SenesTech, Inc. announced its first quarter 2026 financial results, highlighting a 2% revenue increase to $493,000, driven by significant growth in direct-to-consumer and subscription channels despite a planned reduction in third-party e-commerce revenue.

SenesTech, Inc. announces the retirement of CEO Joel L. Fruendt and the appointment of Jamie Bechtel as Interim Executive Chair.

SenesTech, Inc. announced the retirement of CEO Joel L. Fruendt and the appointment of Jamie Bechtel as Interim Executive Chair.

SenesTech, Inc. has formalized the appointment of Michael Edell as Interim Chief Operating Officer with a six-month employment agreement.

SenesTech, Inc. announced record third-quarter 2025 financial results, including 43% revenue growth and improved Adjusted EBITDA, driven by strong Evolve product sales and multi-channel expansion.

SenesTech, Inc. announced the appointment of Michael Edell as Interim Chief Operating Officer, effective October 15, 2025.

SenesTech, Inc. filed a prospectus supplement to register an additional $7.58 million in common stock, continuing its At The Market offering to raise capital.

SenesTech, Inc. announced record second quarter 2025 financial results, driven by 94% growth in Evolve rodent birth control product sales and improved gross profit margins.

SenesTech, Inc. announced the immediate exercise of existing warrants and issuance of new short-term warrants, generating $6.3 million in gross proceeds for working capital.

SenesTech, Inc. announced the expansion of its Board of Directors to seven members and the appointment of Lynn Y. Graham as an independent Class III director, also joining the Commercialization Committee.

SenesTech, Inc. announced the immediate exercise of existing warrants and the issuance of new short-term warrants, expected to generate approximately $4.4 million in gross proceeds for working capital and general corporate purposes.

SenesTech, Inc. has filed a prospectus supplement to register an additional $711,227 of common stock for sale under its existing At The Market Offering Agreement.

SenesTech, Inc. announced the results of its Annual Meeting, where stockholders approved a potential reverse stock split to maintain Nasdaq listing and authorized the issuance of shares underlying warrants, but rejected an increase in shares for its 2018 equity plan.

SenesTech announces a 17% revenue increase in Q1 2025, fueled by a 40% growth in Evolve product sales and record gross profit margins of 65%.

SenesTech reports strong Q4 and full year 2024 results, highlighted by a 70% increase in quarterly revenue and improved gross profit margins, alongside new initiatives to accelerate the path to profitability.

SenesTech, Inc. has entered into agreements for the immediate exercise of outstanding warrants, expecting approximately $1.1 million in gross proceeds and the issuance of new short-term warrants.

SenesTech has appointed Joshua M. Moss, a seasoned investment professional, to its Board of Directors, increasing the board size to six members.

SenesTech announced record revenue and margin performance for the third quarter of 2024, driven by the success of its Evolve product line and strategic expansions.

SenesTech, Inc. has entered into an agreement with existing warrant holders to exercise their warrants for $2.3 million, and in return, the company will issue new warrants.

SenesTech announced record revenue of $874,000 for the first half of 2024, a 62% increase compared to the same period last year, alongside improved gross margins and reduced cash burn.

SenesTech received a notice from Nasdaq regarding non-compliance with audit committee requirements due to a director's departure, triggering a cure period to regain compliance.

SenesTech has announced a 1-for-10 reverse stock split of its common stock, effective July 24, 2024, to increase the per-share price and maintain Nasdaq listing compliance.

SenesTech's annual meeting saw shareholders approve an increase in shares available under the 2018 Equity Incentive Plan and a reverse stock split proposal.

SenesTech, Inc. has entered into an agreement with H.C. Wainwright & Co., LLC to sell up to $1.57 million of its common stock through an at-the-market offering.

SenesTech achieved record quarterly revenue of $415,000 in Q1 2024, a 78% increase year-over-year, primarily driven by the successful launch of its new Evolve rat birth control product.

SenesTech has announced the date for its 2024 Annual Meeting of Stockholders and established new deadlines for shareholder proposals and director nominations due to a change in the meeting date.

SenesTech has received a second extension from Nasdaq to regain compliance with the minimum bid price rule, now until August 19, 2024.